寻明生科获1亿美元融资，加码基座模型开拓AI药物发现新边界

TL;DR - Aureka Biotechnologies raised $100 million in Series B funding to scale its biological foundation models and closed-loop AI drug-discovery infrastructure. The investment supports its shift from improving individual discovery tasks toward modeling and designing complex biological systems.

• Funding will expand AuraIDE’s training for de novo molecular design, structure modeling, functional prediction, and multi-objective optimization.
• Its Lab-in-the-Loop system feeds high-throughput experiments and single-cell functional screens back into model training and reinforcement learning.
• AI agents coordinate target analysis, molecule generation, computational evaluation, experiment design, and results analysis.
• Aureka reports strategic pharmaceutical partnerships and multimillion-dollar commercial revenue, while pursuing a longer-term biological world model.